Investor's Business Daily on MSN

Why psychedelics-tied Compass Pathways reversed its premarket losses

Compass Pathways stock reversed higher Tuesday on positive test results for its psychedelic drug in treatment-resistant depression.

Compass’ psilocybin shows six-month durability in Phase III trial

Compass has already submitted for approval of its psilocybin-based therapy to the FDA following previous Phase III success.

Compass Pathways Clears Another Hurdle – Builds Stronger FDA Case For Its Much-Awaited Depression Therapy

Compass Pathways posted 26-week data from its trial evaluating COMP360, showing rapid and durable benefits, while maintaining ...

Compass gains on new late-stage trial data for psychedelic therapy in depression

Compass Pathways (CMPS) stock rises as the company posts new late-stage trial data for its psychedelic therapy COMP360 ...

Compass Pathways highlights long-term data from resistant depression, backs 2027 launch timeline

Compass Pathways plc CMPS on Wednesday reported 26-week results from Part B of its Phase 3 COMP006 trial, reinforcing the ...

Compass Falls After Psilocybin Data Leave Investors Wanting More

Compass Pathways Plc shares fell almost 10% Tuesday after a pivotal study of its experimental psilocybin-based therapy ...